SEC Form 4 · accession 0001209191-17-006848
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacques Dumas
Officer — Chief ScientificOfficer
Period of report
Jan 30, 2017
Accepted (ET)
Feb 1, 2017 · 6:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Jan 31, 2017 | A | 30,000 | A | — | — | Common Stock | 30,000 | 30,000 | D |
| Employee Stock Option (Right to Buy)F3 | $3.69 | Jan 30, 2017 | A | 140,000 | A | — | Jan 29, 2027 | Common Stock | 140,000 | 140,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration.
- F2These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2020.
- F3Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/30/2021.